- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04722146
A Study of Teclistamab With Other Anticancer Therapies in Participants With Multiple Myeloma (MajesTEC-2)
April 23, 2024 updated by: Janssen Research & Development, LLC
A Multi-arm Phase 1b Study of Teclistamab With Other Anticancer Therapies in Participants With Multiple Myeloma
The purpose of this study is to characterize the safety and tolerability of teclistamab when administered in different combination regimen and to identify the optimal dose(s) of teclistamab combination regimens.
Study Overview
Status
Active, not recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
140
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Fitzroy, Australia, 3065
- St. Vincent's Hospital Melbourne
-
Melbourne, Australia, 3004
- Alfred Health
-
Waratah, Australia, 2298
- Calvary Mater Newcastle Hospital
-
-
-
-
-
Edegem, Belgium, 2650
- UZA
-
Gent, Belgium, 9000
- UZ Gent
-
-
-
-
-
Lyon Cedex 8, France, 69373
- Centre Leon Berard
-
Nantes Cedex 1, France, 44093
- CHU Nantes
-
Pessac cedex, France, 33604
- CHU de Bordeaux - Hospital Haut-Leveque
-
Rennes, France, 35000
- Chu Rennes Hopital Pontchaillou
-
TOULOUSE Cedex 9, France, 31059
- Institut Universitaire du cancer de Toulouse-Oncopole
-
-
-
-
-
London, United Kingdom, NW1 2BU
- University College Hospital
-
Manchester, United Kingdom, M20 4BX
- The Christie NHS Foundation Trust
-
Surrey, United Kingdom, SM2 5PT
- The Royal Marsden NHS Trust Sutton
-
-
-
-
Alabama
-
Birmingham, Alabama, United States, 35294
- University of Alabama at Birmingham
-
-
California
-
San Francisco, California, United States, 94143
- University of California San Francisco
-
-
Colorado
-
Denver, Colorado, United States, 80218
- Colorado Blood Cancer Institute
-
-
Georgia
-
Atlanta, Georgia, United States, 30322
- Emory University
-
-
Indiana
-
Indianapolis, Indiana, United States, 46202
- Indiana University Melvin and Bren Simon Cancer Center
-
-
Missouri
-
Saint Louis, Missouri, United States, 63110-1032
- Washington University School of Medicine
-
-
New Jersey
-
Hackensack, New Jersey, United States, 07601
- Hackensack University Medical Center
-
-
New York
-
New York, New York, United States, 10021
- Memorial Sloan-Kettering Cancer Center
-
New York, New York, United States, 10065
- Weill Cornell Medical College
-
-
North Carolina
-
Charlotte, North Carolina, United States, 28204
- Levine Cancer Institute
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, United States, 15232
- University of Pittsburgh Medical Center
-
-
Tennessee
-
Nashville, Tennessee, United States, 37203
- Tennessee Oncology
-
-
Washington
-
Seattle, Washington, United States, 98109
- Seattle Cancer Care Alliance
-
-
Wisconsin
-
Milwaukee, Wisconsin, United States, 53226
- Medical College of Wisconsin
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Have documented initial diagnosis of multiple myeloma according to international myeloma working group (IMWG) diagnostic criteria
- Meet treatment regimen-specific requirements as follows: Treatment Regimen A (teclistamab [tec]-daratumumab [dara]-pomalidomide [pom]) only: Participant has relapsed or refractory multiple myeloma and has received 1 to 3 prior lines of therapy, including exposure to a proteasome inhibitor (PI) and lenalidomide; Treatment Regimen B (tec-dara-lenalidomide [len]-bortezomib [bor]) only: Participant has newly diagnosed or relapsed/refractory multiple myeloma and is naive to treatment with lenalidomide; Treatment Regimen C (tec-nirogacestat [niro]) only: Participant has relapsed or refractory multiple myeloma and has 1) received 3 or more prior lines of therapy or 2) is double refractory to a PI and an immunomodulatory drug (IMiD) and triple exposed to a PI, an IMiD, and an anti-cluster of differentiation (CD)38 monoclonal antibody (mAb); Treatment Regimen D (tec-len) only: Participant has multiple myeloma and has received greater than or equal to (>=) 2 prior lines of therapy, including exposure to a PI, an IMiD, and an anti-CD38 mAb; Treatment Regimen E (tec-dara-len) only: Participant has newly diagnosed multiple myeloma or if previously treated has received 1 to 3 prior lines of therapy, including exposure to a PI and an IMiD; Treatment Regimen F (tec-dara-len-bor) only: Participant has newly diagnosed multiple myeloma
- Have measurable disease at screening as defined by at least one of the following: serum M-protein level >= 1.0 gram/deciliter (g/dL); or urine M-protein level >= 200 milligrams (mg)/24 hours; or light chain multiple myeloma: serum immunoglobulin (Ig) free light chain (FLC) >= 10 milligram/deciliter (mg/dL) and abnormal serum Ig kappa lambda FLC ratio
- A woman of childbearing potential must have a negative serum (beta human chorionic gonadotropin [hCG]) pregnancy test at screening and a negative urine or serum pregnancy test within 24 hours before the start of study treatment administration and must agree to further serum or urine pregnancy tests during the study
- A woman must agree not to donate eggs (ova, oocytes) for the purposes of assisted reproduction during the study and for at least 100 days after the last dose of study treatment
Exclusion Criteria:
- Prior treatment with any therapy that targets B-cell maturation antigen (BCMA): This exclusion does not apply to Treatment Regimen C
- Live, attenuated vaccine within 30 days before the first dose of study treatment
- Received a cumulative dose of corticosteroids equivalent to >= 140 mg of prednisone within the 14-day period before the start of study treatment administration
- Active central nervous system (CNS) involvement or exhibition of clinical signs of meningeal involvement of multiple myeloma. If either is suspected, brain magnetic resonance imaging (MRI) and lumbar cytology are required
- Known to be seropositive for human immunodeficiency virus
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Treatment Regimen A: Teclistamab + Daratumumab + Pomalidomide
Participants will receive teclistamab plus daratumumab plus pomalidomide.
|
Participants will receive teclistamab.
Other Names:
Participants will receive daratumumab.
Participants will receive pomalidomide.
|
Experimental: Treatment Regimen B: Teclistamab + Daratumumab + Lenalidomide + Bortezomib (21-day Cycles)
Participants will receive teclistamab plus daratumumab plus lenalidomide plus bortezomib in 21-day cycles.
|
Participants will receive teclistamab.
Other Names:
Participants will receive daratumumab.
Participants will receive lenalidomide.
Participants will receive bortezomib.
|
Experimental: Treatment Regimen C: Teclistamab + Nirogacestat
Participants will receive teclistamab plus nirogacestat.
|
Participants will receive teclistamab.
Other Names:
Participants will receive nirogacestat.
|
Experimental: Treatment Regimen D: Teclistamab + Lenalidomide
Participants will receive teclistamab plus lenalidomide.
|
Participants will receive teclistamab.
Other Names:
Participants will receive lenalidomide.
|
Experimental: Treatment Regimen E: Teclistamab + Daratumumab + Lenalidomide
Participants will receive teclistamab plus daratumumab plus lenalidomide.
|
Participants will receive teclistamab.
Other Names:
Participants will receive daratumumab.
Participants will receive lenalidomide.
|
Experimental: Treatment Regimen F: Teclistamab + Daratumumab + Lenalidomide + Bortezomib (28-day Cycles)
Participants will receive teclistamab plus daratumumab plus lenalidomide plus bortezomib in 28-day cycles.
|
Participants will receive teclistamab.
Other Names:
Participants will receive daratumumab.
Participants will receive lenalidomide.
Participants will receive bortezomib.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants with Incidence of Adverse Events (AEs)
Time Frame: Up to 2 year and 5 months
|
An AE can be any unfavorable and unintended sign (including an abnormal finding), symptom, or disease temporally associated with the use of a medicinal (investigational or non-investigational) product, whether or not related to that medicinal (investigational or non-investigational) product.
|
Up to 2 year and 5 months
|
Number of Participants with AEs by Severity
Time Frame: Up to 2 year and 5 months
|
Number of participants with AEs by severity will be reported.
|
Up to 2 year and 5 months
|
Number of Participants with Abnormalities in Laboratory Values
Time Frame: Up to 2 year and 5 months
|
Number of participants with abnormalities in laboratory values (such as serum chemistry, hematology) will be reported.
|
Up to 2 year and 5 months
|
Number of Participants with Dose-Limiting Toxicity (DLT)
Time Frame: Up to Cycle 2 Day 21 (each cycle is of 28 days for Treatment Regimen A and 21 days for Treatment Regimen B)
|
The Dose Limiting Toxicities (DLTs) are based on drug related adverse events and defined as any of the following events: hematological / non hematological toxicity of Grade 3 or higher.
|
Up to Cycle 2 Day 21 (each cycle is of 28 days for Treatment Regimen A and 21 days for Treatment Regimen B)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Overall Response Rate (ORR)
Time Frame: Up to 2 year and 5 months
|
ORR is defined as the proportion of participants who achieve partial response (PR) or better according to the international myeloma working group (IMWG) 2016 criteria.
|
Up to 2 year and 5 months
|
Very Good Partial Response (VGPR) or Better Response Rate
Time Frame: Up to 2 year and 5 months
|
VGPR or better response rate is defined as the proportion of participants who achieve a VGPR or better response (stringent complete response [sCR]+ complete response [CR]+VGPR) according to the IMWG 2016 criteria.
|
Up to 2 year and 5 months
|
Complete Response (CR) or Better Response Rate
Time Frame: Up to 2 year and 5 months
|
CR or better response rate is defined as the proportion of participants who achieve a CR or better response (sCR+CR) according to the IMWG 2016 criteria.
|
Up to 2 year and 5 months
|
Stringent Complete Response (sCR) Rate
Time Frame: Up to 2 year and 5 months
|
sCR rate is defined as the proportion of participants who achieve an sCR according to the IMWG 2016 criteria.
|
Up to 2 year and 5 months
|
Duration of Response
Time Frame: Up to 2 year and 5 months
|
Duration of response is defined as time from date of initial documentation of a response (PR or better) to date of first documented evidence of progressive disease (PD), per IMWG criteria.
|
Up to 2 year and 5 months
|
Time to Response
Time Frame: Up to 2 year and 5 months
|
Time to response is defined as the time between date of first dose of study treatment and the first efficacy evaluation at which the participant has met all criteria for PR or better.
|
Up to 2 year and 5 months
|
Serum Concentrations of Teclistamab
Time Frame: Up to 2 year and 5 months
|
Serum concentrations of teclistamab will be reported.
|
Up to 2 year and 5 months
|
Serum Concentrations of Daratumumab
Time Frame: Up to 2 year and 5 months
|
Serum concentrations of daratumumab will be reported.
|
Up to 2 year and 5 months
|
Serum Concentrations of Nirogacestat
Time Frame: Up to 2 year and 5 months
|
Serum concentration of nirogacestat will be reported.
|
Up to 2 year and 5 months
|
Number of Participants with Presence of Anti-Drug Antibodies to Teclistamab
Time Frame: Up to 2 year and 5 months
|
Number of participants with anti-drug antibodies to teclistamab will be reported for all treatment regimens.
|
Up to 2 year and 5 months
|
Number of Participants with Presence of Anti-Drug Antibodies to Daratumumab
Time Frame: Up to 2 year and 5 months
|
Number of participants with anti-drug antibodies to daratumumab will be reported for Treatment Regimen A, B, E and F.
|
Up to 2 year and 5 months
|
Number of Participants with Presence of Anti-Drug Antibodies to Recombinant Human Hyaluronidase PH20 Enzyme (rHuPH20)
Time Frame: Up to 2 year and 5 months
|
Number of participants with anti-drug antibodies to rHuPH20 will be reported for Treatment Regimen A, B, E and F.
|
Up to 2 year and 5 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Study Director: Janssen Research and Development, LLC Clinical Trial, Janssen Research and Development LLC
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
March 12, 2021
Primary Completion (Estimated)
October 31, 2024
Study Completion (Estimated)
February 24, 2025
Study Registration Dates
First Submitted
January 20, 2021
First Submitted That Met QC Criteria
January 20, 2021
First Posted (Actual)
January 25, 2021
Study Record Updates
Last Update Posted (Estimated)
April 24, 2024
Last Update Submitted That Met QC Criteria
April 23, 2024
Last Verified
April 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Cardiovascular Diseases
- Vascular Diseases
- Immune System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Lymphoproliferative Disorders
- Immunoproliferative Disorders
- Hematologic Diseases
- Hemorrhagic Disorders
- Hemostatic Disorders
- Paraproteinemias
- Blood Protein Disorders
- Multiple Myeloma
- Neoplasms, Plasma Cell
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antineoplastic Agents
- Immunologic Factors
- Angiogenesis Inhibitors
- Angiogenesis Modulating Agents
- Growth Substances
- Growth Inhibitors
- Gamma Secretase Inhibitors and Modulators
- Pomalidomide
- Lenalidomide
- Daratumumab
- Bortezomib
- Nirogacestat
Other Study ID Numbers
- CR108927
- 2020-004404-33 (EudraCT Number)
- 64007957MMY1004 (Other Identifier: Janssen Research & Development, LLC)
- 2023-503440-14-00 (Registry Identifier: EUCT number)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
YES
IPD Plan Description
The data sharing policy of the Janssen Pharmaceutical Companies of Johnson & Johnson is available at www.janssen.com/clinical-trials/transparency.
As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Multiple Myeloma
-
Lawson Health Research InstituteThe Ottawa Hospital; Hamilton Health Sciences Corporation; Dalhousie University; Niagara Health SystemActive, not recruitingMultiple Myeloma in Relapse | Multiple Myeloma With Failed Remission | Multiple Myeloma Stage I | Multiple Myeloma Progression | Multiple Myeloma Stage II | Multiple Myeloma Stage IIICanada
-
National Cancer Institute (NCI)Active, not recruitingSmoldering Multiple Myeloma | Refractory Multiple Myeloma | DS Stage I Multiple Myeloma | DS Stage II Multiple Myeloma | DS Stage III Multiple MyelomaUnited States
-
Fred Hutchinson Cancer Research Center/University...National Cancer Institute (NCI)CompletedStage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
-
Case Comprehensive Cancer CenterNational Cancer Institute (NCI)TerminatedStage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
-
Mayo ClinicCompletedMultiple Myeloma | Stage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
-
National Cancer Institute (NCI)TerminatedStage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
-
National Cancer Institute (NCI)CompletedStage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
-
City of Hope Medical CenterCompletedStage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
-
University of WashingtonNational Cancer Institute (NCI)TerminatedStage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)CompletedStage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
Clinical Trials on Teclistamab
-
Janssen Research & Development, LLCRecruitingHematological MalignanciesUnited States, Netherlands, Spain, France, Sweden
-
Janssen-Cilag Ltd.RecruitingRelapsed/Refractory Multiple Myeloma (RRMM)Spain, France
-
Multiple Myeloma Research ConsortiumNot yet recruitingRefractory Multiple Myeloma | Relapse Multiple Myeloma
-
Janssen Research & Development, LLCNo longer available
-
Janssen Research & Development, LLCApproved for marketingRelapsed or Refractory Multiple Myeloma
-
Janssen Pharmaceutical K.K.Active, not recruitingHematologic MalignanciesJapan
-
Janssen Research & Development, LLCActive, not recruitingHematological MalignanciesCanada, United States, France, Italy, United Kingdom, Germany, Belgium, Netherlands, Spain, Sweden, China
-
SCRI Development Innovations, LLCJanssen Research & Development, LLCRecruiting
-
Jack KhouriNot yet recruitingMultiple Myeloma | Refractory Multiple Myeloma | Cytokine Release Syndrome | Immune Effector Cell Associated Neurotoxicity SyndromeUnited States
-
University Health Network, TorontoJanssen Inc.Not yet recruitingMultiple Myeloma | Relapsed Cancer | Refractory Cancer